Therapeutics News and Research

RSS

Orexigen presents findings on obesity drug candidates

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, has presented the results of a preclinical study that further supports the Company's understanding of an aspect of the mechanism of action of Contrave, one of its two late-stage obesity drug candidates.

24 Oct 2007

Advances in drug screening

With the discovery of suitable molecular targets - cellular molecules along pathways crucial for sustaining the life of cancer cells - comes the perplexing dilemma of where to find the next therapeutics that will bind to and disable those targets.

23 Oct 2007

Two carotid stenting trials show results comparable to AHA guidelines

Two carotid stenting trials examining patient outcomes demonstrated results that are comparable to guidelines established by the American Heart Association (AHA) for patients treated with carotid artery surgery.

23 Oct 2007

GenVec receives extra funding for adenovector-based HIV vaccines program

GenVec, Inc. has announced that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has executed its sixth option period (year seven) under its multi-year collaboration with GenVec to develop and manufacture novel adenovector-based HIV vaccines.

22 Oct 2007

New biomaterial from Rutgers

A revolutionary, new biomaterial, developed at the New Jersey Center for Biomaterials (NJCBM) at Rutgers University, has moved from the lab bench to field testing in record time.

19 Oct 2007

Oral medication restores missing protein in boys with muscular dystrophy

PTC124, an oral medication that changes the way muscle cells interpret genetic information, holds promise as a treatment for some patients with Duchenne muscular dystrophy (DMD), the Muscular Dystrophy Association ( http://www.mda.org/ ) announced today.

19 Oct 2007

New links in the cystic fibrosis chain uncover potential therapeutics

Cystic fibrosis (CF) is an inherited disease caused by mutations in the CFTR gene.

19 Oct 2007

New therapy for chronic spasticity and rigidity

Research led by scientists at the University of California, San Diego (UCSD) School of Medicine has identified a target with potential as an effective new therapy for chronic spasticity and rigidity, a painful condition that often results from spinal cord injury.

17 Oct 2007

New knowledge about basic cancer biology

Merging technological innovations and new knowledge about basic cancer biology, cancer researchers now target specific molecules involved in critical chemical pathways of cancerous cells.

17 Oct 2007

Findings could lead to new therapy for spinal cord injury

17 Oct 2007

Landmark stent trial to be presented at TCT 2007

The Cardiovascular Research Foundation (CRF) will release results of its landmark research study, HORIZONS AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) at the nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

16 Oct 2007

Agency for Healthcare Research and Quality expands research on therapeutics program

The Agency for Healthcare Research and Quality, part of the U.S. Department of Health and Human Services, announced the award of $41.6 million over the next 4 years for a new coordinating center and 10 research centers as part of its Centers for Education and Research on Therapeutics (CERTs) program.

16 Oct 2007

The importance of the endocannabinoid-system

Cannabis (marijuana) is the most widely produced plant-based illicit drug worldwide and the illegal drug most frequently used in Europe.

15 Oct 2007

First high-res 3D structures of first mammalian GRP94 protein solved

Dr. Dan Gewirth, Hauptman-Woodward senior research scientist, has just solved the structure of the first mammalian GRP94 protein implicated in immune diseases such as sepsis, AIDS and certain cancers.

15 Oct 2007

$Accentia announces investigational new drug application for Revimmune for refractory MS$

Accentia announces investigational new drug application for Revimmune for refractory MS

Accentia Biopharmaceuticals has announced that it met with the Food and Drug Administration (FDA) on September 26, 2007 for a scheduled pre-Investigational New Drug (pre-IND) meeting on Revimmune.

10 Oct 2007

Study links chemical to inhibited milk synthesis, secretion in humans

University of Cincinnati (UC) researchers have identified the neurotransmitter serotonin as the chemical responsible for inhibiting milk production and secretion in human mammary glands.

9 Oct 2007

New insight on jumping genes

Keck Graduate Institute (KGI) announced that Dr. Animesh Ray, KGI professor and director of KGI's PhD program, has published a paper in the international online journal PLoS ONE that sheds new light on the evolution of moveable genetic elements, or "jumping genes."

9 Oct 2007

Sir Martin Evans wins Nobel prize for stem cell research

Medical Research Council funded scientist Sir Martin Evans, has been awarded the Nobel Prize in Physiology or Medicine for 2007 alongside Mario R. Capecchi and Oliver Smithies for their discoveries of "principles for introducing specific gene modifications in mice by the use of embryonic stem cells".

9 Oct 2007

Taking antidepressants with painkillers dangerous

Taking antidepressants together with painkillers can substantially increase the risk of bleeding from the stomach, according to new research by the University of East Anglia.

9 Oct 2007

SSRIs may double risk of gastrointestinal bleeding

New research shows that selective serotonin reuptake inhibitors (SSRIs), a group of drugs commonly used to treat depression, may double the risk of gastrointestinal bleeding, according to researchers from Wake Forest University School of Medicine and colleagues.

9 Oct 2007